# Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling

> **NIH NIH U01** · CLEVELAND CLINIC LERNER COM-CWRU · 2024 · $25,129

## Abstract

ABSTRACT
Targeted cancer therapy, in the form of tyrosine kinase inhibitors, has been a game changer for patients with
cancers driven by activating mutations in genes encoding these proteins. Yet, while we are seeing overall survival
beneﬁts unlike with any new agents in over a decade, cures remain elusive, or non-existent, as resistance to
these agents reliably emerges. The process driving this resistance is the same process that drives invasive
pests' resistance to pesticides, pathogens' resistance to antibiotics and many other phenomena in life: Darwinian
evolution. While this is being increasingly recognized, it has yet to change the paradigm in cancer research where
most projects are centered on a hunt for actionable mutations conferring resistance. While these secondary
mutations are often druggable themselves, we submit that this is a never-ending race that evolution will always
win. We hypothesize that an approach centered instead on studying the evolutionary process itself can help
break this cycle. While there is a robust theoretical literature modeling cancer evolution with mathematics, there
is a relative paucity of research connecting this theory to empirical biology or clinical medicine. To address this
shortcoming, we have worked for the past three years to develop a ﬁrst-in-class evolutionary game assay to
directly measure the eco-evolutionary interactions driving the emergence of resistance in vitro. This assay allows
us to directly parameterize an evolutionary game theoretic model with empiric studies in any system. Here, we
propose to extend our initial observations revealing a vast heterogeneity in evolutionary dynamics under different
agents in vitro to allow for clinical translation by extend ouring assay to an in vivo system. We posit that the new
methods and understanding we will gain during this proposal will beneﬁt the cancer research community as a
whole, as well as provide novel opportunities for therapeutic interventions aimed at disrupting and altering the
evolutionary mechanisms driving resistance.

## Key facts

- **NIH application ID:** 11062602
- **Project number:** 3U01CA280829-01S2
- **Recipient organization:** CLEVELAND CLINIC LERNER COM-CWRU
- **Principal Investigator:** Andriy Marusyk
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $25,129
- **Award type:** 3
- **Project period:** 2024-06-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11062602

## Citation

> US National Institutes of Health, RePORTER application 11062602, Extending experimental evolutionary game theory in cancer in vivo to enable clinical translation: integrating spatio-temporal dynamics using mathematical modeling (3U01CA280829-01S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11062602. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
